$TOMZ

TOMI Environmental Solutions, Inc.

No enriched coverage for $TOMZ in the last 7 days.

No SEC Form 4 filings for $TOMZ in the last 30 days.

Low

TOMI Environmental Solutions 10-K: $5.64M Revenue, $(0.19) EPS

TOMI Environmental Solutions reported fiscal 2025 net sales of $5.636 million and a basic and diluted loss per share of $(0.19), with revenue decline attributed to the timing of large equipment purchases. Despite lower sales, the company improved its gross profit margin to 54.6% and narrowed its net loss to $(3.749) million due to cost management and prior-year inventory adjustments. TOMI also highlighted strategic OEM partnerships, product expansion into new markets like aerospace and cell & gene therapy, and securing a significant commercial SIS installation.

TOMI sales fell in 2025, but it says Q1 is already ahead

TOMI Environmental Solutions reported a revenue decline to $5.64M in 2025 from $7.74M in 2024, attributed to deferred capital expenditure projects by customers amidst economic uncertainties. Despite the sales drop, the company maintained a strong gross margin of approximately 55% and narrowed its net loss, while expanding internationally and growing its sales backlog. TOMI anticipates improved performance in Q1 2026, driven by a robust pipeline of integration projects and continued focus on global market expansion and operational efficiencies.

TOMI Environmental Solutions Receives Biocidal Product Approvals in Great Britain and Northern Ireland

TOMI Environmental Solutions, Inc. has received official authorization from the Health and Safety Executive (HSE) for its Binary Ionization Technology (BIT) solution and SteraMist iHP brand in Great Britain and Northern Ireland. These approvals allow for the expanded use of their disinfection products in various sectors including healthcare, industrial, commercial, and hospitality. The company is also optimistic about a forthcoming approval under the EU Biocidal Products Regulation for further European market expansion.